Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women
Journal
International Journal of Rheumatic Diseases
Journal Volume
12
Journal Issue
3
Pages
216-224
Date Issued
2009
Author(s)
Kung A.W.-C.
Rachman I.A.
Adam J.M.F.
Roeshadi D.
Torralba T.
Navarra S.
Gamilla Z.
Ca?ete A.
de la Rosa M.
Lin H.-Y.
Soong Y.K.
Lan J.-L.
Hsu H.-C.
Tu S.-T.
Lin R.-M.
Yuktanandana P.
Songpatanasilp T.
Ngarmukos S.
Soontrapa S.
Soontrapa S.
Rojanasthien S.
Luevitoonvechkij S.
Leerapan T.
Albert A.
Vanbelle S.
Abstract
Aim: his study assesses the impact of serum carboxy-terminal collagen crosslinks (CTX) bone marker feedback (BMF) on adherence to ibandronate treatment in Asian postmenopausal women with osteoporosis. Methods: This was a 12-month (6-monthly phased), randomized, prospective, open-label, multi-center study conducted in 596 (of 628 enrolled) postmenopausal women with osteoporosis (? 85 years old) who were na?ve, lapsed, or current bisphosphonate users. Patients were randomized into two arms: serum CTX BMF at 3 months versus no-BMF. Once-monthly 150 mg ibandronate tablet was administered for 12 months and adherence to therapy was assessed at 6 and 12 months. In addition, patient satisfaction and safety of ibandronate treatment were also assessed. Results: Serum CTX BMF at 3 months showed no impact on adherence. The proportions of adherent patients were comparable in the BMF versus no-BMF arms (92.6% vs. 96.0%, P = 0.16); overall, serum CTX levels were similar for adherent and non-adherent patients. However, BMF patients felt more informed about their osteoporosis (P < 0.001) and more satisfied (P < 0.01) than no-BMF patients. Conclusions: The Asian postmenopausal osteoporosis patients in this study had a high adherence rate to once-monthly ibandronate therapy. Use of serum CTX BMF had no further impact on increasing adherence, but increased treatment satisfaction. ? 2009 Asia Pacific League of Associations for Rheumatology and Blackwell Publishing Asia Pty Ltd.
Subjects
Adherence; Bone marker; Compliance; Feedback; Ibandronate; Osteoporosis
SDGs
Other Subjects
bisphosphonic acid derivative; carboxy terminal telopeptide; ibandronic acid; aged; article; Asian; blood sampling; cardiovascular disease; clinical trial; comparative study; connective tissue disease; controlled clinical trial; controlled study; drug safety; female; gastrointestinal disease; hematologic disease; human; ileus; infection; major clinical study; metabolic disorder; multicenter study; musculoskeletal disease; neurologic disease; open study; patient compliance; patient education; patient information; patient satisfaction; postmenopause; postmenopause osteoporosis; priority journal; protein blood level; psychopathy; randomized controlled trial; Administration, Oral; Aged; Aged, 80 and over; Asian Continental Ancestry Group; Biological Markers; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Patient Satisfaction
Type
journal article